Efficacy and Mechanisms of Change of Two Brief Treatments for Borderline Personality Disorder (GPMDBT)

November 12, 2026 updated by: Ueli Kramer, University of Lausanne Hospitals

Efficacy and Mechanisms of Change of Two Brief Treatments for Borderline Personality Disorder: a Randomized Controlled Trial

The present non-inferiority randomized controlled trial aims at comparing the efficacy of 6-month Good Psychiatric Management to 6-month Dialectical-Behavior Therapy for personality disorder (and borderline personality disorder). In addition, six mechanisms of change are systematically tested within a within- and between-person design. In-session physiology assesses the emotional engagement and non-verbal synchrony, while out-of-session self-report questionnaires (i.e., diary) assess generalized skills and capabilities.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

144

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Canton of Vaud
      • Lausanne, Canton of Vaud, Switzerland, 1004
        • Recruiting
        • Lausanne University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Borderline Personality Disorder; Moderate Personality Disorder

Exclusion Criteria:

  • neurological disorder; schizophrenia; self-reported cardiological diagnosis; self-reported pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 6 month Good Psychiatric Management

Use of interpersonal hypersensitivity model

Active Comparator: 6 month Dialectical Behavior Therapy

use of chain analyses and emotion regulation strategies according to protocol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ZAN-BPD
Time Frame: 6 months

Zanarini Borderline Personality Disorder Scale (Zanarini, 2003) ranges between 0 and 36, higher scores mean more symptom load (so worse outcome).

6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2026

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

August 31, 2030

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2026-00651
  • SNSF (Other Grant/Funding Number: Swiss National Science Foundation)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.